Use of hospitalization and pharmaceutical prescribing data to compare the prevaccination burden of varicella and herpes zoster in Australia

Epidemiology and Infection

Volumn 131, Issue 1, 2003, Pages 675-682

  MacIntyre, C R ^a   Chu, C P ^b   Burgess, M A ^a  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CHICKENPOX VACCINE; VARICELLA ZOSTER VACCINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; AUSTRALIA; CHICKENPOX; CHILD; COMMUNITY; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FATALITY; HEALTH SURVEY; HERPES ZOSTER; HOSPITALIZATION; HUMAN; INCIDENCE; INFANT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MEDICAL INFORMATION SYSTEM; MORBIDITY; NONHUMAN; PRESCRIPTION; VACCINATION; VARICELLA ZOSTER VIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUSTRALIA; CHICKENPOX; CHILD; CHILD, PRESCHOOL; FEMALE; HERPES ZOSTER; HOSPITALIZATION; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MORBIDITY; PHYSICIAN'S PRACTICE PATTERNS; POPULATION SURVEILLANCE; VACCINATION;

EID: 0042355240     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0950268803008690     Document Type: Article

References (30)

1. Gershon AA, Takahashi H, White CJ. Varicella vaccine. In: Plotkin S, Orenstein WA, eds. Vaccines. Philadelphia: WB Saunders Company, 1988: 476-477.
2. Preblud SR, Orenstein WA, Bart KJ. Varicella: clinical manifestations, epidemiology and health impact in children. Ped Infect Dis 1984; 3: 505-509.
3. Guess HA, Broughton DD, Melton LJ 3rd, Kurland LT. Population-based studies of varicella complications. Pediatrics 1986; 78: 723-727.
4. Brody MB, Moyer D. Varicella-zoster virus infection. The complex prevention-treatment picture. Postgrad Med 1997; 102: 187-190, 192-194.
5. Lin F, Hadler JL. Epidemiology of primary varicella and herpes zoster hospitalizations: the pre-varicella vaccine era. J Infect Dis 2000; 181: 1897-1905.
6. Guess HA, Broughton DD, Melton LJ 3rd, Kurland LT. Epidemiology of herpes zoster in children and adolescents: a population-based study. Pediatrics 1985; 76: 512-517.
7. Gershon AA. Prevention and treatment of VZV infections in patients with HIV. Herpes 2001; 8: 32-36.
8. Forrest J, Mego S, Burgess M. Congenital and neonatal varicella in Australia. J Paed Child Health 2000; 36: 108-113.
9. Bowsher D. The lifetime occurrence of herpes zoster and prevalence of post-herpetic neuralgia: a retrospective survey in an elderly population. Europ J Pain 1999; 3: 335-342.
10. Brisson M, Edmunds WJ, Law B, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001; 127: 305-314.
11. Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001; 19: 3076-3090.
12. Hata A, Asanuma H, Rinki M, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. New Engl J Med 2002; 347: 26-34.
13. Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 2002; 287: 606-611.
14. National Coding Centre. ICD-9-CM. The Official NCC Australian Version. Sydney: Faculty of Health Sciences, University of Sydney, 1995.
15. Nowgesic E, Skowronski D, King A, Hockin J. Direct costs attributed to chickenpox and herpes zoster in British Columbia - 1992 to 1996. Canada Commun Dis Rep 1999; 25: 100-104.
16. Anonymous. Australian demographic statistics. Canberra: Australian Bureau of Statistics, 2001.
17. Statistics ABo. Projection of the population of Australia's states and territories 1989-2031. Canberra: Commonwealth Government Printers, 1990.
18. Chant KG, Sullivan EA, Burgess MA, et al. Varicella-zoster virus infection in Australia. Aust New Zealand J Public Health 1998; 22: 413-418.
19. Coplan P, Black S, Rojas C, et al. Incidence and hospitalization rates of varicella and herpes zoster before varicella vaccine introduction: a baseline assessment of the shifting epidemiology of varicella disease. Pediatric Infect Dis J 2001; 20: 641-645.
20. Arbeter AM, Starr SE, Preblud SR, et al. Varicella vaccine trials in healthy children. A summary of comparative and follow-up studies. Am J Dis Child 1984; 138: 434-438.
21. Beutels P, Clara R, Tormans G, Van Doorslaer E, Van Damme P. Costs and benefits of routine varicella vaccination in German children. J Infect Dis 1996; 174: S335-S341.
22. Coudeville L, Paree F, Lebrun T, Sailly J. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine 1999; 17: 142-151.
23. Scuffham PA, Lowin AV, Burgess MA. The cost-effectiveness of varicella vaccine programs for Australia. Vaccine 1999; 18: 407-415.
24. Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect 2000; 125: 651-669.
25. Brisson M, Edmunds WJ, Gay NJ, Miller E. Varicella vaccine and shingles. JAMA 2002; 287: 2211-2212.
26. Garnett GP, Grenfell BT. The epidemiology of varicella-zoster virus infections: the influence of varicella on the prevalence of herpes zoster. Epidemiol Infect 1992; 108: 513-528.
27. Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002; 20: 2500-2507.
28. Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 2002; 360: 678-682.
29. MacIntyre CR, Ackland MJ, Chandraraj EJ, Pilla JE. Accuracy of ICD-9-CM codes in hospital morbidity data, Victoria: implications for public health research. Aust New Zealand J Public Health 1997; 21: 477-482.
30. Hope-Simpson RE. Infectiousness of communicable diseases in the household. Lancet 1952; 249: 499-504.